Antiparkinsonism drugs

Details Antiparkinsonism drugs Antiparkinsonism drugs

2006-10-31

2006-10-31

Marschel, Ardin H. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S359000

Reexamination Certificate

active

07129256

ABSTRACT:
A compound represented by the formula:wherein A is thiazolyl or the like, X is a bond or the like, m is an integer of 0 to 4, Y is optionally substituted alkyl or the like, Z is a substituent represented by the formula:wherein R3is hydrogen atom or the like, R4and R5are each independently hydrogen atom or the like, W is —(CH2)n— (n is 0, 1, 2 or 3) or the like, a prodrug thereof, its pharmaceutically acceptable salt, or its solvate is useful as a composition for prevention or treatment of Parkinson's disease.

REFERENCES:
patent: 4045556 (1977-08-01), Schwertner et al.
patent: 4100152 (1978-07-01), Fujino et al.
patent: 4386073 (1983-05-01), Kisfaludy et al.
patent: 5118670 (1992-06-01), Wurtman et al.
patent: 6319902 (2001-11-01), Sugawara et al.
patent: 0123444 (1984-10-01), None
patent: 0225796 (1987-06-01), None
patent: 0373904 (1990-06-01), None
patent: 373904 (1990-06-01), None
patent: 0384380 (1990-08-01), None
patent: 0933379 (1999-08-01), None
patent: 933379 (1999-08-01), None
patent: 1519636 (1978-08-01), None
patent: 2161486 (1986-01-01), None
patent: 60023326 (1985-02-01), None
patent: 61027982 (1986-02-01), None
patent: 62234029 (1987-10-01), None
patent: WO 96/11209 (1996-04-01), None
Suzuki et al., J. Med. Chem., vol. 33, pp. 2130-2137 (1990).
Ogasawara et al., Biomedical Research, vol. 14, No. 5, pp. 317-328 (1993).
Oka, et al., Arzneim-Forsch./Drug Res., vol. 39 (I), No. 3, pp. 297-303 (1989).
Matsushita, et al., European Journal of Pharmacology, vol. 276, pp. 177-182 (1995).
Miyamoto et al., European Journal of Pharmacology, vol. 271, pp. 357-366 (1994).
Miwa et al., European Journal of Pharmacology, vol. 277, pp. 63-69 (1995).
Ogata et al., Journal of the Neurological Sciences, vol. 159, pp. 135-139, (1998).
Matsuura et al., Brain Research, vol. 733, pp. 101-104, (1996).
Shiozaki et al., Psychopharmacology, vol. 147, pp. 90-95 (1999).
Elsevier, Amsterdam-New York-Oxford, Design of prodrugs, pp. 7-24, (1985).
Hsiao et al., Synthetic Communications, vol. 20, No. 22, pp. 3507-3517 (1990).
Paquette et al., Tetrahedron, vol. 27, pp. 2599-2607, (1971).
“The Japanese Journal of Pharmacology” p. 371, (Mar. 22-25, 1992).
Fukuchi et al., Arzneim-Forsch./Drug Res. vol. 48, No. (I), pp. 353-359 (1998).
Renming et al., European Journal of Pharmacology, vol. 223, pp. 185-192 (1992).
Kabayama et al., Brain Research, vol. 372, pp. 394-399 (1986).
Ogata, Akihiko, et al. J. Neurol. Sci., vol. 159, No. 2, pp. 135-139, 1998.

Affiliated with

Also associated with

Rating

Antiparkinsonism drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiparkinsonism drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiparkinsonism drugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3672324